Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,142 across all filing types
Latest filing 2010-08-17 Capital/Financing Update
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
EIGHT-K DEBT OFFERING
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 12, 2010. It announces the commencement and pricing of a public offering of debt notes by Johnson & Johnson, including details about the notes and the closing date. The document includes legal opinions and exhibits related to the debt offering. The content focuses on a capital raising event through debt issuance, which aligns with updates on company financing activities. The document length is 2595 characters, which is relatively short but contains substantive information about the financing event itself, not just an announcement of a report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2010-08-17 English
424B2
Capital/Financing Update Classification · 100% confidence The document is a Prospectus Supplement filed pursuant to Rule 424(b)(2) related to the registration and offering of debt securities (notes) by Johnson & Johnson. It includes detailed information about the terms of the notes, interest rates, redemption options, underwriting, use of proceeds, and legal disclaimers. The document is a formal offering prospectus supplement, which is a type of capital markets disclosure related to financing activities. It is not an annual or quarterly report, audit report, earnings release, or any other type of financial report. It is specifically related to the issuance of debt securities and the associated registration statement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2010-08-14 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a Pricing Term Sheet for a debt offering (2.950% Senior Unsecured Notes due 2020) by Johnson & Johnson. It includes details such as coupon rate, maturity date, size, underwriting discount, trade date, expected settlement date, and anticipated credit ratings. The document is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. This type of document is an update on the company's capital raising activity and financing terms, not a full financial report or earnings release. It is not a regulatory filing or announcement of a report publication. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on financing terms, supporting this classification with high confidence.
2010-08-13 English
FREE WRITING PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a Free Writing Prospectus (FWP) filed pursuant to Rule 433, containing a pricing term sheet for a 4.500% Senior Unsecured Notes due 2040. It details the terms of a debt offering including coupon, maturity, size, underwriting discount, ratings, and settlement dates. This is a capital markets document related to a financing activity, specifically a debt issuance. It is not an annual or interim report, earnings release, or any other type of report. The document is short (2295 characters) and is a direct disclosure of financing terms, not an announcement of a report publication. Therefore, it fits the category of Capital/Financing Update (CAP).
2010-08-13 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Preliminary Prospectus Supplement filed pursuant to Rule 424(B)(3) related to a securities offering by Johnson & Johnson. It includes detailed information about the terms of notes being offered, interest rates, redemption options, underwriting, and use of proceeds. It references registration statements and SEC rules related to securities offerings. The document is not an annual or quarterly report, earnings release, or management discussion. It is a detailed offering document related to capital raising and financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual prospectus supplement, not just an announcement of a report.
2010-08-12 English
FORM 10-Q
Interim / Quarterly Report Q2 2010
2010-08-11 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.